NCT05087342View on ClinicalTrials.gov

Latino Semaglutide Study

PHASE3CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

May 29, 2024

Study Completion Date

May 29, 2024

Conditions
ObesityObesity; DrugOverweight or ObesityWeight LossWeight Loss TrajectoryWeight, Body
Interventions
DRUG

Semaglutide 2.4mg

The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.

DRUG

Placebo

A placebo will be given to the control group per the schedule outlined in the armed description.

Trial Locations (1)

92350

Loma Linda University Health, Loma Linda

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Loma Linda University

OTHER